Bowlus CL, Holcombe JH, Wintle ME,Maggs DG. Exenatide effects on diabetes,obesity, cardiovascular risk factors andhepatic biomarkers in patients with type 2diabetes treated for at least 3 years. CurrMed Res Opin 2008;24:275–286 17. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L.Exenatide once weekly versus twice dailyfor the treatment of type 2 diabetes: arandomised, open-label, non-inferioritystudy. Lancet 2008;372:1240–1250 18. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K.Effects of once-weekly dosing of a long-acting release formulation of exenatide onglucose control and body weight in sub-jects with type 2 diabetes. Diabetes Care2007;30:1487–1493 19. World Medical Association Declaration of Helsinki. Recommendations guiding phy-sicians in biomedical research involvinghuman subjects. JAMA 1997;277:925–926 20. Fineman MS, Bicsak TA, Shen LZ, Taylor